Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

Novartis's product lineup is anchored by several key growth drivers, including Cosentyx, Pluvicto, Kisqali, and Scemblix. These products are expected to play a crucial role in achieving the ...

While Novartis’ financial stability and growth trend of new products such as Kisqali and Scemblix, among others, offsets the potential risks associated with the partnership and mitigates the ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

It is one of three major Novartis products that are nearing the end of their patent lives, along with cancer drug Tasigna (nilotinib) and Promacta (eltrombopag) for thrombocytopaenia, which ...